Journal of Cancer Research and Therapeutics Close
 

Figure 4:A schematic diagram of epidermal growth factor receptor showing the distribution of exons in the extracellular domain (epidermal growth factor binding), transmembrane domain, and intracellular domain (comprising of the tyrosine kinase and autophosphorylation regions). Exons 18–21 in the tyrosine kinase region where the relevant mutations are located are expanded (represented by the purple bar), and a detailed list of epidermal growth factor receptor mutations in these exons that are associated with sensitivity (purple boxes at bottom) or resistance (red boxes in the middle) to gefitinib or erlotinib is shown. The sensitizing (epidermal growth factor receptor E746 T751>VP) and resistance-mediated (epidermal growth factor receptor A647) mutations described in our case are shown in this figure are highlighted in red boxes

Figure 4:A schematic diagram of epidermal growth factor receptor showing the distribution of exons in the extracellular domain (epidermal growth factor binding), transmembrane domain, and intracellular domain (comprising of the tyrosine kinase and autophosphorylation regions). Exons 18–21 in the tyrosine kinase region where the relevant mutations are located are expanded (represented by the purple bar), and a detailed list of epidermal growth factor receptor mutations in these exons that are associated with sensitivity (purple boxes at bottom) or resistance (red boxes in the middle) to gefitinib or erlotinib is shown. The sensitizing (epidermal growth factor receptor E746 T751>VP) and resistance-mediated (epidermal growth factor receptor A647) mutations described in our case are shown in this figure are highlighted in red boxes